272 related articles for article (PubMed ID: 19318390)
1. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study.
Nannini C; Crowson CS; Matteson EL; Moder KG
Lupus; 2009 Apr; 18(5):394-9. PubMed ID: 19318390
[TBL] [Abstract][Full Text] [Related]
2. Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Dittrich K; Ross S; Benz K; Amann K; Dötsch J
Klin Padiatr; 2009 Dec; 221(7):425-9. PubMed ID: 20013565
[TBL] [Abstract][Full Text] [Related]
3. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years.
Posalski JD; Ishimori Ml; Wallace DJ; Weisman MH
Lupus; 2009 May; 18(6):516-21. PubMed ID: 19395453
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of mycophenolate mofetil in patients with systemic lupus erythematosus.
Riskalla MM; Somers EC; Fatica RA; McCune WJ
J Rheumatol; 2003 Jul; 30(7):1508-12. PubMed ID: 12858449
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature.
Conti F; Ceccarelli F; Perricone C; Massaro L; Cipriano E; Pacucci VA; Truglia S; Miranda F; Morello F; Alessandri C; Spinelli FR; Valesini G
Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
[TBL] [Abstract][Full Text] [Related]
7. Flares in pediatric systemic lupus erythematosus.
Weiss JE; Sison CP; Ilowite NT; Gottlieb BS; Eberhard BA
J Rheumatol; 2007 Jun; 34(6):1341-4. PubMed ID: 17477466
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center.
Lourdudoss C; Vollenhoven Rv
Lupus; 2014 Mar; 23(3):299-304. PubMed ID: 24399811
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
Zahr N; Arnaud L; Marquet P; Haroche J; Costedoat-Chalumeau N; Hulot JS; Funck-Brentano C; Piette JC; Amoura Z
Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558
[TBL] [Abstract][Full Text] [Related]
10. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine.
Fischer-Betz R; Specker C; Brinks R; Aringer M; Schneider M
Rheumatology (Oxford); 2013 Jun; 52(6):1070-6. PubMed ID: 23382355
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.
Tselios K; Gladman DD; Su J; Urowitz MB
J Rheumatol; 2016 Mar; 43(3):552-8. PubMed ID: 26773121
[TBL] [Abstract][Full Text] [Related]
12. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus.
Galarza-Maldonado C; Kourilovitch MR; Molineros JE; Cardiel MH; Zurita L; Soroka NF; Yagur VY; Doukh N; Cervera R
Autoimmun Rev; 2010 Dec; 10(2):108-11. PubMed ID: 20804861
[TBL] [Abstract][Full Text] [Related]
13. A national survey on current use of mycophenolate mofetil for childhood-onset systemic lupus erythematosus in Japan.
Hara R; Miyazawa H; Nishimura K; Momoi T; Nozawa T; Kikuchi M; Sakurai N; Kizawa T; Shimamura S; Yasuda S; Hiromura K; Sada KE; Kawaguchi Y; Tamura N; Takei S; Takasaki Y; Atsumi T; Mori M
Mod Rheumatol; 2015; 25(6):858-64. PubMed ID: 26215483
[TBL] [Abstract][Full Text] [Related]
14. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.
Djabarouti S; Breilh D; Duffau P; Lazaro E; Greib C; Caubet O; Saux MC; Pellegrin JL; Viallard JF
Arthritis Res Ther; 2010; 12(6):R217. PubMed ID: 21176194
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
Dall'Era M
Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus.
Fassbinder T; Saunders U; Mickholz E; Jung E; Becker H; Schlüter B; Jacobi AM
Arthritis Res Ther; 2015 Apr; 17(1):92. PubMed ID: 25890338
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus.
Buratti S; Szer IS; Spencer CH; Bartosh S; Reiff A
J Rheumatol; 2001 Sep; 28(9):2103-8. PubMed ID: 11550982
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review.
Mok CC
Scand J Rheumatol; 2007; 36(5):329-37. PubMed ID: 17963161
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis.
Wilson EC; Jayne DR; Dellow E; Fordham RJ
Rheumatology (Oxford); 2007 Jul; 46(7):1096-101. PubMed ID: 17409128
[TBL] [Abstract][Full Text] [Related]
20. Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
J Clin Pharm Ther; 2012 Apr; 37(2):217-20. PubMed ID: 21517926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
